Breast Carcinoma — Research

Breast Carcinoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed3 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-11	437,649	`("Breast Carcinoma"[tiab] OR "Breast Cancer"[tiab] OR "Mammary Carcinoma"[tiab] OR "Carcinoma of Breast"[tiab] OR "Carcinoma of the Breast"[tiab])`	2026-09-11	pubmed
Last 5 years	2021-01-01 → 2026-12-31	134,009	`("Breast Carcinoma"[tiab] OR "Breast Cancer"[tiab] OR "Mammary Carcinoma"[tiab] OR "Carcinoma of Breast"[tiab] OR "Carcinoma of the Breast"[tiab]) AND (2021/01/01:2026/12/31[dp])`	2026-09-11	pubmed
Last 12 months	2025-09-11 → 2026-09-11	27,661	`("Breast Carcinoma"[tiab] OR "Breast Cancer"[tiab] OR "Mammary Carcinoma"[tiab] OR "Carcinoma of Breast"[tiab] OR "Carcinoma of the Breast"[tiab]) AND (2025/09/11:2026/09/11[dp])`	2026-09-11	pubmed

Data updated 20 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (75)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 26–50 of 75 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial.
· Lancet Oncol · 2015 · PMID 26596672 · validated civic_curation pubmed
Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer.
· Clin Cancer Res · 2015 · PMID 25370464 · validated civic_curation pubmed
MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
· Oncotarget · 2016 · PMID 26921265 · validated civic_curation